Literature DB >> 31897736

Dronedarone blockage of the tumor-related Kv10.1 channel: a comparison with amiodarone.

T A Meléndez1, A Huanosta-Gutiérrez1, C Barriga-Montoya1, M González-Andrade2, F Gómez-Lagunas3.   

Abstract

Kv10.1 (Eag1, or KCNH1) is a human potassium-selective channel associated with tumor development. In this work, we study the interaction of the drug dronedarone with Kv10.1. Dronedarone presents two chemical modifications aimed to lessen side effects produced by its parent molecule, the antiarrhythmic amiodarone. Hence, our observations are discussed within the framework of a previously reported interaction of amiodarone with Kv10.1. Additionally, we show new data regarding the interaction of amiodarone with the channels. We found that, unexpectedly, the effect of dronedarone on Kv10.1 differs both quantitatively and qualitatively to that of amiodarone. Among other observations, we found that dronedarone seems to be an open-pore blocker, in contrast to the reported behavior of amiodarone, which seems to inhibit from both open and closed states. Additionally, herein we provide evidence showing that, in spite of their chemical similarity, these molecules inhibit the K+ conductance by binding to non-overlapping, independent (non-allosterically related) sites. Also, we show that, while amiodarone inhibits the Cole-Moore shift, dronedarone is unable to inhibit this voltage-dependent characteristic of Kv10.1.

Entities:  

Keywords:  Amiodarone; Cole-Moore shift; Dronedarone; Eag1; Kv10.1; Potassium channels

Year:  2020        PMID: 31897736     DOI: 10.1007/s00424-019-02342-8

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  37 in total

1.  Correction to: Inhibition of the K+ conductance and Cole-Moore shift of the oncogenic Kv10.1 channel by amiodarone.

Authors:  C Barriga-Montoya; A Huanosta-Gutiérrez; A Reyes-Vaca; A Hernández-Cruz; A Picones; F Gómez-Lagunas
Journal:  Pflugers Arch       Date:  2018-06       Impact factor: 3.657

2.  Class III antiarrhythmic drug dronedarone inhibits cardiac inwardly rectifying Kir2.1 channels through binding at residue E224.

Authors:  Panagiotis Xynogalos; Claudia Seyler; Daniel Scherer; Christoph Koepple; Eberhard P Scholz; Dierk Thomas; Hugo A Katus; Edgar Zitron
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-09-04       Impact factor: 3.000

3.  Oncogenic potential of EAG K(+) channels.

Authors:  L A Pardo; D del Camino; A Sánchez; F Alves; A Brüggemann; S Beckh; W Stühmer
Journal:  EMBO J       Date:  1999-10-15       Impact factor: 11.598

4.  Potassium ion current in the squid giant axon: dynamic characteristic.

Authors:  K S COLE; J W MOORE
Journal:  Biophys J       Date:  1960-09       Impact factor: 4.033

5.  A voltage-driven switch for ion-independent signaling by ether-à-go-go K+ channels.

Authors:  Andrew P Hegle; Daniel D Marble; Gisela F Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-13       Impact factor: 11.205

6.  Inhibition of HERG potassium channels by celecoxib and its mechanism.

Authors:  Roman V Frolov; Irina I Ignatova; Satpal Singh
Journal:  PLoS One       Date:  2011-10-24       Impact factor: 3.240

7.  Voltage-dependent gating of KCNH potassium channels lacking a covalent link between voltage-sensing and pore domains.

Authors:  Éva Lörinczi; Juan Camilo Gómez-Posada; Pilar de la Peña; Adam P Tomczak; Jorge Fernández-Trillo; Ulrike Leipscher; Walter Stühmer; Francisco Barros; Luis A Pardo
Journal:  Nat Commun       Date:  2015-03-30       Impact factor: 14.919

8.  Cancer metastasis and EGFR signaling is suppressed by amiodarone-induced versican V2.

Authors:  Hung-Chieh Lee; Mai-Yan Su; Hao-Chan Lo; Chin-Chieh Wu; Jia-Rung Hu; Dao-Ming Lo; Tsu-Yi Chao; Huai-Jen Tsai; Ming-Shen Dai
Journal:  Oncotarget       Date:  2015-12-15

9.  Interaction of tetraethylammonium ion derivatives with the potassium channels of giant axons.

Authors:  C M Armstrong
Journal:  J Gen Physiol       Date:  1971-10       Impact factor: 4.086

10.  Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment.

Authors:  A B Nagaraj; Q Q Wang; P Joseph; C Zheng; Y Chen; O Kovalenko; S Singh; A Armstrong; K Resnick; K Zanotti; S Waggoner; R Xu; A DiFeo
Journal:  Oncogene       Date:  2017-10-02       Impact factor: 9.867

View more
  1 in total

Review 1.  Targeting Ion Channels for Cancer Treatment: Current Progress and Future Challenges.

Authors:  Alina L Capatina; Dimitris Lagos; William J Brackenbury
Journal:  Rev Physiol Biochem Pharmacol       Date:  2022       Impact factor: 5.545

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.